Profound Medical Corp Dossier
Qualitative Analysis
Business overview
Profound Medical Corp. is a commercial-stage medical technology company focused on developing and marketing customizable, incision-free, image-guided therapies for the ablation of diseased tissue. The company's flagship platform is TULSA-PRO, a minimally invasive, AI-powered, MRI-guided, and robotically driven transurethral ultrasound ablation system designed to treat prostate disease while preserving patient quality of life. Additionally, Profound commercializes Sonalleve, an innovative therapeutic platform utilizing real-time MRI and thermometry for non-invasive treatment of uterine fibroids, adenomyosis, and palliative pain management of bone metastases.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Accelerating the commercial adoption of the TULSA-PRO system in the United States by leveraging favorable CMS reimbursement rates (Urology APC Level 7 codes) and pursuing national and regional commercial payer coverage.
Expected impact: Aims to unlock a projected annual revenue potential of $85 million by expanding patient access and hospital adoption.
Developing and launching 'TULSA+', an integrated solution combining the TULSA-PRO platform with Siemens Healthineers' MAGNETOM Free.Max MRI system under a co-sales and co-marketing agreement.
Expected impact: Provides a comprehensive, pre-integrated solution for MRI-guided prostate therapy, lowering the barrier to entry for hospitals without existing compatible MRI hardware.
Developing and commercializing the next-generation TULSA-AI volume reduction software module to optimize treatment planning and workflow efficiency.
Expected impact: Aims to expand the addressable patient population from 200,000 to 600,000 annually by streamlining workflows and enhancing clinical precision.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Enables the creation and distribution of the 'TULSA+' integrated offering, combining TULSA-PRO with Siemens' MAGNETOM Free.Max MRI to expand market reach.
Terms: Co-sales and co-marketing collaboration; specific financial splits are not publicly disclosed.
Marks the first U.S. national commercial payer coverage for the TULSA Procedure, adding approximately 8.5 million covered lives and establishing a precedent for other national payers.
Terms: Provides reimbursement coverage for eligible members undergoing the TULSA Procedure.
Expands commercial distribution of Profound's technologies into key Asia-Pacific (APAC) markets.
Terms: Exclusive or semi-exclusive regional distribution terms; specific financial details are not disclosed.